Skip to main content

Table 3 Main Characteristics of the Analyzed Trials

From: R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature

Study

Patient Population

Treatment

(N)

CR

(n; %)

PR

(n; %)

OR

(n; %)

Criteria

Czuczman et al [4]: Prospective; Single treatment group; Intent to treat trial

N-40; 18 years and older with CD 20+ follicular lymphoma

R-CHOP

N = 40

22; 55%

16; 40%

38; 95%

Table 1

Hiddemann W et al. [5]: Prospective, randomized, non-crossover, open label multicenter phase 3 trial

N = 428; 18 years and older with untreated advanced stage follicular lymphoma

R-CHOP

(N = 223)

vs.

CHOP

(N = 205)

44; 20%

35; 17%

170; 77%

150; 73%

214; 96%

185; 90%

IWG[13]

Domingo-Domenech et al. [6]: Prospective, non-randomized, non-crossover, open label multicenter phase 2 trial

N = 16; 18 to 70 years age with CD 20+ follicular lymphoma

R-CHOP

(N = 16)

12; 75%

2; 13%

14; 88%

IWG [13]

Marcus R et al. [7]: Prospective, randomized, non-crossover trial

N = 321; 18 years or older, untreated CD 20+ follicular lymphoma

R-CVP

(N = 162)

vs.

CVP

(N = 159)

66; 41%

16; 11%

65; 40%

74; 47%

131; 81%

90; 57%

IWG[13]